Geode Capital Management
EPRX icon

Geode Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Geode Capital Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
36,211
+10,598
+41% +$73.1K ﹤0.01% 3849
2026
Q1 		$185K Buy
25,613
+11,714
+84% +$94.3K ﹤0.01% 3935
2025
Q4 		$105K Buy
+13,899
New +$85.7K ﹤0.01% 4082

Other funds holding EPRX

Beutel, Goodman & Co
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Scotia Capital
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PFM Health Sciences
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Great Point Partners
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Ikarian Capital
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management's EPRX Position: Q2 2026 in Review

Geode Capital Management increased its Eupraxia Pharmaceuticals (EPRX) stake by 41% in Q2 2026, buying an estimated $73.1K and bringing the position to 36,211 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #3849.

Geode Capital Management first reported a position in EPRX in Q4 2025 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Geode Capital Management held 36,211 shares of Eupraxia Pharmaceuticals worth $239K as of Q2 2026.
  • Geode Capital Management bought 10,598 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $73.1K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3849 holding.
  • Geode Capital Management first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.